This is a non-interventional post-marketing surveillance study designed to fulfill a post-approval commitment (PAC) to the China FDA (CFDA). The study is focused on the incidence of expected and unexpected drug-related adverse events (AEs) and serious adverse events (SAEs) of daclatasvir hydrochloride (DCV)-based regimens in routine clinical use in patients with chronic hepatitis C (CHC).
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.
[Translation] An open-label, randomized, phase 2B study of dasatinib versus imatinib in patients with chronic myeloid leukemia who have not achieved a best response to 400 mg imatinib for 3 months
The primary objective of this study was to compare the 12-month MMR rate after first-line imatinib day 1 in patients who did not achieve optimal response to first-line imatinib (BCR-ABL > 10% IS) and were randomized to receive dasatinib 100 mg QD or any dose of imatinib at month 3.
100 Clinical Results associated with Bristol-Myers Squibb SRL
Login to view more data
0 Patents (Medical) associated with Bristol-Myers Squibb SRL
Login to view more data
1
Literatures (Medical) associated with Bristol-Myers Squibb SRL
ClinicoEconomics and Outcomes Research
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.